imaginima/E+ via Getty Images
Northwest Biotherapeutics (OTCQB:NWBO) just released its 10-K. Investors have a major problem with NWBO – after 16 months of data lock, there’s very little information available on TLD or topline data. So I took the latest 10-K and the one from last year, put them in a PDF comparison tool, and tried to see in a direct and understandable manner what has changed at the company in the last one year. This article will mostly discuss those changes and the latest update about the compassionate use patient at their Sawston facility.
To give you an idea of how the system works, here’s a sentence from this year’s 10-K:
Key experts at certain specialized service providers have been unavailable for periods of time.
If you look at the same sentence from the previous year’s 10-K:
Key experts at certain specialized service providers have been unavailable for periods of time due to illness in their family.
So we can understand that those people that were ill are not so any longer, however, the problem with unavailability persists, one way or the other. To do this sort of analysis manually would have taken hours. The tool makes it quicker. Let me now look for major changes here, ones that reflect what the company has been doing, if anything, in the past year.
So, about the Sawston facility, here’s what 2021 said:
The final stage of development of the initial production capacity (the Performance Qualification stage) is under way, and when…
